Breaking News Instant updates and real-time market news.

AVGO

Broadcom

$263.89

2.24 (0.86%)

, GE

General Electric

$17.90

0.235 (1.33%)

12:37
12/07/17
12/07
12:37
12/07/17
12:37

On The Fly: Top stock stories at midday

Stocks opened little changed and remained in a narrow range throughout the morning. However, the major averages have moved toward session highs near noon, with the Nasdaq the strongest of the equity indexes. Oil prices have rebounded after beginning the day in negative territory, with the price of crude now higher by a bit over 1%. ECONOMIC EVENTS: In the U.S., initial jobless claims dipped 2,000 to 236,000 in the first week of December. A report on consumer credit growth in October is expected at 3 pm ET. COMPANY NEWS: Shares of Broadcom (AVGO) have advanced 1% after the company's earnings were solid, its guidance came in ahead of expectations and its dividend was hiked by more than anticipated... GE (GE) announced that it plans to reduce its global headcount in its Power division by approximately 12,000 positions. While Power "will remain a work in progress in 2018," GE Power president and CEO Russell Stokes said the plan "will position us for 2019 and beyond." MAJOR MOVERS: Among the noteworthy gainers was Sage Therapeutics (SAGE), which surged 78% after it reported "positive" top-line results from its Phase 2 clinical trial of SAGE-217 for the treatment of major depressive disorder. Also higher was Entellus Medical (ENTL), which rallied 50% after it agreed to be acquired by Stryker (SYK) for $24 per share in cash. Among the notable losers after reporting quarterly results were Duluth Holdings (DLTH), Verint (VRNT), and Ciena (CIEN), which fell 16%, 6%, and 3.5%, respectively. INDEXES: Near midday, the Dow was up 97.87, or 0.41%, to 24,238.78, the Nasdaq was up 43.18, or 0.64%, to 6,819.56, and the S&P 500 was up 9.25, or 0.35%, to 2,638.52.

AVGO

Broadcom

$263.89

2.24 (0.86%)

GE

General Electric

$17.90

0.235 (1.33%)

SAGE

Sage Therapeutics

$91.90

2.11 (2.35%)

ENTL

Entellus Medical

$16.01

-0.25 (-1.54%)

SYK

Stryker

$151.06

-0.7 (-0.46%)

DLTH

Duluth Holdings

$19.28

0.55 (2.94%)

VRNT

Verint

$42.55

-0.4 (-0.93%)

CIEN

Ciena

$20.20

-0.97 (-4.58%)

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

AVGO Broadcom
$263.89

2.24 (0.86%)

12/07/17
OPCO
12/07/17
NO CHANGE
Target $315
OPCO
Outperform
Broadcom price target raised to $315 from $300 at Oppenheimer
Oppenheimer analyst Rick Schafer raised his price target for Broadcom to $315 from $300 following Q4 results. The analyst reiterates an Outperform rating on the shares.
12/07/17
COWN
12/07/17
NO CHANGE
Target $320
COWN
Outperform
Broadcom price target raised to $320 from $270 at Cowen
Cowen analyst Karl Ackerman raised his price target on Broadcom to $320 from $270 as he sees several growth opportunities yet to emerge that will make organic growth targets seem "nonsensical" over the next couple of years. He also said margins and free cash flow still have room to grow thanks to the company's economic moat. Ackerman reiterated his Outperform rating on Broadcom shares.
12/07/17
CHLM
12/07/17
NO CHANGE
Target $330
CHLM
Buy
Broadcom price target raised to $330 from $290 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss raised his price target for Broadcom (AVGO) to $330 from $290 noting that guidance was better than feared due to slight wireless growth and extra week. The analyst believes the company continues to benefit from its 40% content growth phone over phone in Apple's (AAPL) iPhone 8/8 Plus/X, driving October results toward the high end of its guided range. He reiterates a Buy rating on Broadcom's shares.
12/07/17
BERN
12/07/17
NO CHANGE
Target $325
BERN
Outperform
Broadcom price target raised to $325 from $300 at Bernstein
Bernstein analyst Stacy Rasgon raised her price target for Broadcom to $325 from $300 following a "strong" quarter. The analyst reiterates an Outperform rating on the shares.
GE General Electric
$17.90

0.235 (1.33%)

11/28/17
DBAB
11/28/17
NO CHANGE
Target $171
DBAB
Buy
Honeywell price target raised to $171 from $154 at Deutsche Bank
Deutsche Bank analyst John Inch raised his price target for Honeywell (HON) to $171 following recent meetings with management. The shares closed yesterday up 77c to $150.43. The target represents a 20 times forward multiple to the analyst's 2019 earnings forecast. Inch continues to believe Honeywell could become the "next multi-industry investment leader" over the coming decade as General Electric (GE) "further retrenches to preserve cash." Honeywell can pivot towards faster growth with a balance sheet that allows for billions in future growth investments, the analyst tells investors in a research note. He keeps a Buy rating on the shares.
11/14/17
11/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Deane Dray saying that he now expects the turnaround at the company to be more protracted than previously anticipated, noting the roadmap laid out by new CEO John Flannery fell short of expectations regarding the scope of the business model/portfolio changes. 2. Phillips 66 (PSX) downgraded to Underweight from Equal Weight at Barclays analyst Paul Cheng saying the company's diversified business model will likely drive underperformance in a strong margin uptrend environment for U.S. refiners. 3. Hilton (HLT) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Stephen Grambling citing the recent outperformance of the stock for the rating change, but he expects consistent double-digit earnings growth on low single-digit RevPAR. 4. PulteGroup (PHM) downgraded to Neutral from Buy at Buckingham with the firm citing recent share strength and raised its price target to $33 from $31. 5. Albemarle (ALB) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter downgraded Albemarle (ALB) to Hold from Buy while raising his price target for the shares to $150 from $130. Following a field trip to China, Begleiter believes new lithium processing capacity is coming, which should begin to pressure prices by 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/17
COWN
11/14/17
NO CHANGE
COWN
Market Perform
Woodward may have negative read through from GE Power guidance, says Cowen
Cowen analyst Guatam Khanna noted that General Electric (GE) has reduced its outlook for its Power segment and said it will seek to pare back delivery of gas turbine part orders that have already been placed. All of this may add pressure to Woodward's (WWD) FY18 industrial segment guidance, said Khanna, who has a Market Perform rating on Woodward shares.
11/21/17
DBAB
11/21/17
NO CHANGE
Target $15
DBAB
Sell
Deutsche Bank cuts target on Sell-rated GE to Street-low $15
Deutsche Bank analyst John Inch believes General Electric should trade at a valuation discount given its "still aggressive" accounting, cash flow and debt pressures, and the potential for additional lawsuits. The analyst remains surprised by management's "upbeat tone/pitch." GE continues to call 2018 a "reset" and "trough" year even though billions of dollars of cost savings are expected to flow into numbers next year from downsizing and other restructuring actions, Inch tells investors in a research note. These costs are no longer going to run through the presentation of earnings as GE adopts a "more aggressive adjusted earnings" presentation framework, the analyst adds. He feels GE has been asserting the strength of its portfolio excluding Power, while pointing to cash flow and profit upside, "despite the recent collapse in both financial measures." The analyst cut his price target for the shares to $15 from $18 and reiterates a Sell rating on General Electric. The price target represents the lowest among those published by Wall Street sell-side analysts. The stock closed yesterday at $17.98.
SAGE Sage Therapeutics
$91.90

2.11 (2.35%)

12/07/17
ADAM
12/07/17
NO CHANGE
Target $191
ADAM
Buy
Canaccord ups Sage target to $191 on 'unequivocally positive' data
Canaccord Genuity analyst John Newman raised his price target for Sage Therapeutics to $191 from $140 after the company reported Phase II trial results for SAGE-217 in major depressive disorder. The stock in early trading is up 66%, or $60.86, to $152.76. The data are "unequivocally positive" with a statistically significant effect versus placebo after the first dose, Newman tells investors in a research note. By comparison, currently marketed selective serotonin reuptake inhibitor depression drugs often take months to show an effect, the analyst points out. Further, he views SAGE-217's safety as "clean" and "highly encouraging." While admitting some investors may want to take profits on today's profits, Newman thinks Sage's long-range prospects are positive and he maintains a Buy rating on the shares.
12/07/17
LEER
12/07/17
NO CHANGE
Target $246
LEER
Outperform
Sage Therapeutics price target raised to $246 from $123 at Leerink
12/07/17
RBCM
12/07/17
NO CHANGE
Target $280
RBCM
Outperform
Sage Therapeutics price target raised to $280 from $137 at RBC Capital
12/07/17
RBCM
12/07/17
NO CHANGE
Target $280
RBCM
Top Pick
RBC puts Street-high price target of $280 on Sage Therapeutics
RBC Capital analyst Brian Abrahams raised his price target for Sage Therapeutics to $280 from $137 after the company reported Phase II trial results for SAGE-217 in major depressive disorder. The target represents the high among Wall Street sell-side analysts, according to Bloomberg. The "outstanding" data show a "differentiated profile that could be game-changing" if replicated in Phase III, and may lead to $3.8B in out-year sales, Abrahams tells investors in a research note. The analyst still sees "considerable fundamental upside" in shares despite today's rally. He also sees a "good likelihood" of takeout at a valuation premium to current levels. Abrahams keeps an Outperform rating on Sage Therapeutics. The stock in midday trading is up 78%, or $72.10, to $164.00.
ENTL Entellus Medical
$16.01

-0.25 (-1.54%)

02/22/17
BTIG
02/22/17
DOWNGRADE
BTIG
Neutral
Entellus Medical downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Entellus Medical to Neutral after the company guided to14%-20% 2017 growth and a larger loss than consensus. "Something has gone off course," the analyst writes in a post-earnings research note. He believes the "business is changing."
02/22/17
BOFA
02/22/17
DOWNGRADE
BOFA
Underperform
Entellus Medical downgraded to Underperform from Buy at BofA/Merrill
05/04/17
ADAM
05/04/17
DOWNGRADE
Target $18
ADAM
Hold
Entellus Medical downgraded to Hold from Buy at Canaccord
Canaccord analyst Kyle Rose downgraded Entellus Medical to Hold from Buy and lowered its price target to $18 from $22 saying the soft Q1 report indicates a slowing in the core US business.
12/13/16
PIPR
12/13/16
NO CHANGE
Target $21
PIPR
Overweight
Piper says NICE support of XprESS should help Entellus international growth
After NICE published its recommendation in support of Entellus Medical's XprESS multi-sinus dilation system, Piper Jaffray analyst Matt O'Brien called the news a positive that should help drive adoption outside of the U.S. and support the company's international growth goals. He keeps an Overweight rating and $21 price target on Entellus shares.
SYK Stryker
$151.06

-0.7 (-0.46%)

10/31/17
OPCO
10/31/17
NO CHANGE
Target $156
OPCO
Outperform
Stryker price target raised to $156 from $148 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Stryker to $156 from $148 on higher estimates following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/27/17
COWN
10/27/17
NO CHANGE
Target $166
COWN
Outperform
Stryker Q3 results solid despite challenges, says Cowen
Cowen analyst Joshua Jennings said Stryker reported solid Q3 results despite challenges from a Sage ship-hold and bad weather. The analyst said he is encouraged by the company's increased guidance as margins remain on track. Jennings reiterated his Outperform rating and raised his price target to $166 from $160 on Stryker shares.
11/16/17
BARD
11/16/17
UPGRADE
Target $173
BARD
Outperform
Stryker upgraded to Outperform at Baird
As reported previously, Baird analyst Jeff Johnson upgraded Stryker to Outperform from Neutral reflecting his conviction in the company's ability to deliver double digit EBIT and earnings growth in 2018 based on the firm's positive hospital capital expenditure survey results and growing evidence of accelerating Mako total knee training efforts over the past month or two. Johnson raised his price target to $173 from $161 on Stryker shares.
11/16/17
BARD
11/16/17
UPGRADE
BARD
Outperform
Stryker upgraded to Outperform from Neutral at Baird
DLTH Duluth Holdings
$19.28

0.55 (2.94%)

11/27/17
DADA
11/27/17
NO CHANGE
Target $25
DADA
Buy
Duluth Holdings to benefit from store growth visibility, says DA Davidson
DA Davidson analyst Andrew Burns preview's Thursday's Q3 earnings for Duluth Holdings, saying he is positive on the company's omni-channel positioning, high visibility to store growth, and potential earnings acceleration. While the overall retail environment remains difficult, the analyst writes in his research report, the company has had a better assortment of seasonal products while also lapping the warmer temperatures going into the winter last year. Burns keeps his Buy rating and $25 price target on Duluth.
11/01/17
BMOC
11/01/17
DOWNGRADE
BMOC
Market Perform
Duluth Holdings downgraded to Market Perform from Outperform at BMO Capital
08/23/17
08/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ultragenyx (RARE) downgraded to Hold from Buy at SunTrust, with analyst Edward Nash slashing his price target to $55 from $105 after the company reported negative topline data from the Phase III trial for Ace-ER for GNE myopathy. Nash is disappointed by this first major clinical setback for the company and removed Ace-ER from his valuation models. 2. Duluth Holdings (DLTH) downgraded to Market Perform from Outperform at Raymond James, with analyst Dan Wewer citing increasing industry challenges. Wewer is concerned about increasing promotional activity and aggressive pricing tactics by competitors. 3. Cree (CREE) downgraded to Underweight from Equal Weight at Stephens. 4. Washington Prime (WPG) downgraded to Underperform from Neutral at Boenning & Scattergood by analyst Floris van Dijkum due to a more expensive NAV relative valuation caused by the more than 6% sector outperformance in the current quarter. 5. Baozun (BZUN) downgraded to Hold from Buy at Deutsche Bank by analyst Eileen Deng citing valuation after the stock's 18% rise in the past six months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/17
BMOC
11/01/17
DOWNGRADE
Target $20
BMOC
Market Perform
Duluth Holdings cut to Market Perform at BMO Capital on competitive pressure
As previously noted, BMO Capital analyst John Morris downgraded Duluth Holdings to Market Perform from Outperform and cut his price target to $20 from $30. Morris notes that Duluth peers are offering more promotions, which could pressure the company's earnings into the second half. The analyst also says the unseasonably warm fall weather and California wildfires may impact Q3 results, with risk that the management's Q4 outlook may turn more cautious.
VRNT Verint
$42.55

-0.4 (-0.93%)

05/15/17
OPCO
05/15/17
NO CHANGE
OPCO
FireEye poised for increased demand after ransomware attack, says Oppenheimer
Oppenheimer analyst Shaul Eyal notes that according to media reports, a global ransomware attack was launched and infected up to 200,000 computers in at least 150 countries on Friday. The analyst believes the "biggest ransomware outbreak ever" could serve as a wake-up call for many organizations and countries delaying a review of their cybersecurity hygiene. In that regard, Eyal believes all cybersecurity vendors under his coverage, namely Check Point (CHKP), CyberArk (CYBR), Fortinet (FTNT), Imperva (IMPV), Mimecast (MIME), Palo Alto Networks (PANW), Splunk (SPLK), Symantec (SYMC), Verint (VRNT), but most notably FireEye (FEYE), are poised for increased demand, particularly in the EMEA region where the attacks were largely focused.
03/31/17
IMPC
03/31/17
DOWNGRADE
Target $45
IMPC
In-Line
Verint downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst Jeff Kessler downgraded Verint Systems to In-Line citing valuation following the company's Q4 results. The analyst sees limited potential for "material share price" appreciation over the next year. He raised his price target for the shares to $45 from $43.
03/31/17
03/31/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Corning (GLW) downgraded to Neutral from Buy at Citi with analyst Stanley Kovler saying that while near-trends remain favorable, he sees limited upside to earnings estimates in 2018. The analyst believes the current valuation reflects the solid trends. He raised his price target for the shares to $29 from $28. 2. Nasdaq (NDAQ) downgraded to Sector Perform from Outperform at RBC Capital with analyst Peter Lenardo saying he believes upside is limited given operating margin pressures, moderating near-term growth, and increasing competition. 3. Rent-A-Center (RCII) downgraded to Underweight from Equal Weight at Stephens with analyst Vincent Caintic saying he worries that its share price reflects an optimistic view on near-term performance versus a number of near-term headwinds. 4. Verint (VRNT) downgraded to In-Line from Outperform at Imperial Capital with analyst Jeff Kessler citing valuation following the company's fourth quarter results. 5. JELD-WEN Holding (JELD) downgraded to Neutral from Outperform at Wedbush with analyst Al Kaschalk telling investors shares reflect near-term catalysts and maintained its $34 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
GSCO
08/07/17
UPGRADE
Target $50
GSCO
Conviction Buy
Verint upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Gabriela Borges added Verint to the Conviction Buy List with a $50 price target saying he expects a continued recovery in the Security business to drive operating margins given the strong backlog and heightened geopolitical risk environment.
CIEN Ciena
$20.20

-0.97 (-4.58%)

12/04/17
JEFF
12/04/17
NO CHANGE
Target $32.5
JEFF
Buy
Jefferies likes Ciena's risk/reward heading into 2018
Jefferies analyst George Notter reiterates a Buy rating on Ciena with a $32.50 price target saying he likes for the stock for 2018. The shares are trading "meaningfully below" their historical valuation norms, Notter tells investors in a research note. He sees a "number of avenues" for Ciena to exceed updated views of sales growth for next year, including Verizon's 100G metro project.
11/27/17
BOFA
11/27/17
UPGRADE
BOFA
Buy
Ciena upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Tal Liani upgraded Ciena to Buy and maintained a $28 price target saying shares are at the low end of the historical range and the earnings growth profile is attractive.
11/27/17
11/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying he views Lowe's shares as more attractive following the third quarter beat. 2. T-Mobile (TMUS) upgraded to Buy from Neutral at MoffettNathanson. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS with analyst Michael Leuchten saying concerns of continuing earnings decline and the dividend sustainability are now overdone. 4. Ciena (CIEN) upgraded to Buy from Neutral at BofA/Merrill with analyst Tal Liani saying shares are at the low end of the historical range and the earnings growth profile is attractive. 5. Constellium (CSTM) upgraded to Outperform from Market Perform at Cowen with analyst Novid Russell saying the company's rapid deleveraging has allowed investors to focus on its significant growth projects, attractive end markets, and valuation discount relative to peers. Russell raised his price target to $13 from $11 on Constellium shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/17
GSCO
11/06/17
DOWNGRADE
Target $22
GSCO
Neutral
Finisar downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Doug Clark downgraded Finisar (FNSR) to Neutral and his Telecom Equipment coverage view to Neutral from Attractive citing a more cautious stance on the optical component cycle. The analyst sees softening end markets, rising inventories and industry capacity. For Finisar, which reports earnings in early December, Clark thinks the company's guidance has "significant downside risk" relative to consensus expectations. The analyst cut his price target for the shares to $22 from $27. Finisar closed the trading day down 15c to $19.25. Elsewhere in Telecom Equipment sector, Clark has Buy ratings on Arris (ARRS) and Infinera (INFN), Neutral ratings on Acacia Communications (ACIA), Ciena (CIEN) and Lumentum (LITE), and a Sell rating on Adtran (ADTN).

TODAY'S FREE FLY STORIES

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IMMR

Immersion

$9.56

-0.14 (-1.44%)

17:12
11/16/18
11/16
17:12
11/16/18
17:12
Hot Stocks
Breaking Hot Stocks news story on Immersion »

Man Group reports 4.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$11.95

0.74 (6.60%)

17:10
11/16/18
11/16
17:10
11/16/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Athenex »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

TSRO

Tesaro

$34.96

8.39 (31.58%)

17:08
11/16/18
11/16
17:08
11/16/18
17:08
Recommendations
Tesaro analyst commentary at Piper Jaffray »

Piper Jaffray says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

EEI

Ecology & Environment

$10.50

-2 (-16.00%)

17:05
11/16/18
11/16
17:05
11/16/18
17:05
Hot Stocks
Ecology & Environment receives noncompliance notice from Nasdaq »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$69.29

0.01 (0.01%)

16:58
11/16/18
11/16
16:58
11/16/18
16:58
Hot Stocks
Ameren exec Nelson sells $690,000 worth of common shares »

Ameren SVP, general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQS

Equus II Inc

$1.86

(0.00%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Equus II Inc reports net assets of $46.6M as of September 30 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAPO

Vapotherm

$17.10

-0.42 (-2.40%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Vapotherm »

Redmile Group reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

COTY

Coty

$9.09

0.39 (4.48%)

16:55
11/16/18
11/16
16:55
11/16/18
16:55
Hot Stocks
Coty CEO acquires 2.3M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

NVS

Novartis

$87.74

0.52 (0.60%)

16:54
11/16/18
11/16
16:54
11/16/18
16:54
Upgrade
Novartis rating change at Goldman Sachs »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

VIAB

Viacom

$33.00

1.13 (3.55%)

16:52
11/16/18
11/16
16:52
11/16/18
16:52
Syndicate
Breaking Syndicate news story on Viacom »

Viacom files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.